Search
TBC-3711
go.drugbank.com/drugs/DB05407InvestigationalTBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Acetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalIt is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
Zastumotide
go.drugbank.com/drugs/DB14926InvestigationalIt is under investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck).
RGX-501
go.drugbank.com/drugs/DB17639InvestigationalIt is being investigated for the treatment of homozygous familial hypercholesterolemia.[L46696]
Dabocemagene autoficel
go.drugbank.com/drugs/DB17878InvestigationalDeveloped by Castle Creek Biosciences Inc., dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.[L46797]
Viralym-C
go.drugbank.com/drugs/DB17975InvestigationalIt was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]
DYNE-251
go.drugbank.com/drugs/DB18130InvestigationalIt is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping.
BO-653
go.drugbank.com/drugs/DB19216InvestigationalBO-653 is under investigation in clinical trial NCT00055510 (A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and
Barbital
go.drugbank.com/drugs/DB01483ExperimentalIllicitBarbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug.